prikaz prve stranice dokumenta Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer
  Download
PDF 1.78 MB
Scientific paper - Original scientific paper
Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer
Biomedicines, 12 (2024), 3; 477. https://doi.org/10.3390/biomedicines12030477
Blažeković, Ivan; Šamija, Ivan; Periša, Josipa; Gall Trošelj, Koraljka; Regović Džombeta, Tihana; Radulović, Petra; Romić, Matija; Granić, Roko; Šiško Markoš, Ines; Fröbe, Ana; Kusić, Zvonko; Jukić, Tomislav

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Blažeković, I., Šamija, I., Periša, J., Gall Trošelj, K., Regović Džombeta, T., Radulović, P. ... Jukić, T. (2024). Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer. Biomedicines, 12. (3). doi: 10.3390/biomedicines12030477

Blažeković, Ivan, et al. "Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer." Biomedicines, vol. 12, no. 3, 2024. https://doi.org/10.3390/biomedicines12030477

Blažeković, Ivan, Ivan Šamija, Josipa Periša, Koraljka Gall Trošelj, Tihana Regović Džombeta, Petra Radulović, Matija Romić, et al. "Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer." Biomedicines 12, no. 3 (2024). https://doi.org/10.3390/biomedicines12030477

Blažeković, I., et al. (2024) 'Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer', Biomedicines, 12(3). doi: 10.3390/biomedicines12030477

Blažeković I, Šamija I, Periša J, Gall Trošelj K, Regović Džombeta T, Radulović P, and sur.. Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer. Biomedicines [Internet]. 2024 February 21 [cited 2024 November 25];12(3). doi: 10.3390/biomedicines12030477

I. Blažeković, et al., "Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer", Biomedicines, vol. 12, no. 3, February 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:161168. [Accessed: 25 November 2024]

Metadata
Title (english)Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer
AuthorIvan Blažeković
AuthorIvan Šamija
AuthorJosipa Periša
AuthorKoraljka Gall Trošelj
AuthorTihana Regović Džombeta
AuthorPetra Radulović
AuthorMatija Romić
AuthorRoko Granić
MBZ: 318880
AuthorInes Šiško Markoš
AuthorAna Fröbe
AuthorZvonko Kusić
AuthorTomislav Jukić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Nuclear Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Nuclear Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
The early identification of aggressive forms of cancer is of high importance in treating papillary thyroid cancer (PTC). Disease dissemination is a major factor influencing patient survival. Mutation status of BRAF oncogene, BRAF V600E, is proposed to be an indicator of disease recurrence; however, its influence on PTC dissemination has not been deciphered. This study aimed to explore the association of the frequency of BRAF V600E alleles in PTC with disease dissemination. In this study, 173 PTC samples were analyzed, measuring the proportion of BRAF V600E alleles by qPCR, which was then normalized against the proportion of tumor cells. Semiquantitative analysis of BRAF V600E mutant protein was performed by immunohistochemistry. The BRAF V600E mutation was present in 60% of samples, while the normalized frequency of mutated BRAF alleles ranged from 1.55% to 92.06%. There was no significant association between the presence and/or proportion of the BRAF V600E mutation with the degree of PTC dissemination. However, the presence of the BRAF mutation was significantly linked with angioinvasion. This study’s results suggest that there is a heterogeneous distribution of the BRAF mutation and the presence of oligoclonal forms of PTC. It is likely that the BRAF mutation alone does not significantly contribute to PTC aggressiveness.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 12, no. 3, 477
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12030477
URN:NBNurn:nbn:hr:105:161168
Publication2024-02-21
ProjectNumber: IP-2019-04-1130
Title (croatian): Genetski i epigenetski biljezi kao pokazatelji agresivnosti diferenciranog karcinoma štitnjače
Title (english): Genetic and epigenetic markers as indicators of aggressiveness of differentiated thyroid cancer
Acronym: ThyroGeneMark
Leader: Zvonko Kusić
Jurisdiction: Croatia
Funding stream: Research Projects
Document URLhttps://www.mdpi.com/2227-9059/12/3/477
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-10-22 07:53:59